Expression of mutant Ataxin-1 with an abnormally expanded polyglutamine domain is necessary for the onset and progression of spinocerebellar ataxia type 1 (SCA1).
Introduction
Spinocerebellar ataxia type 1 (SCA1) is a dominantly inherited neurodegenerative disease caused by the abnormal expansion of a CAG codon repeat in the open reading frame of the ATXN1 gene (Orr et al., 1993) . Individuals with SCA1 display a progressive deterioration of balance and gait control, as well as swallowing and breathing difficulties, leading to premature death (Ashizawa et al., 2013; Orr, 2000; Orr et al., 1993; Zoghbi and Orr, 2009 ). Although the Ataxin-1 protein is expressed throughout the brain, and other parts of the body, a preferential loss of cerebellar Purkinje cells and a thinning of the brainstem are the main pathological findings in SCA1 (Seidel et al., 2012; Servadio et al., 1995) . It is unclear what restricts the pathology to these sites, though a number of studies support a role for cell type-specific differences in the regulation of ATXN1 mRNA expression and Ataxin-1 protein-protein interactions (Jafar-Nejad et al., 2011; Rousseaux et al., 2018) .
Multiple cellular pathways are known to post-translationally regulate Ataxin-1 protein levels in the mammalian brain (Bondar et al., 2018; Jafar-Nejad et al., 2011; Lai et al., 2011; Park et al., 2013; Pérez Ortiz et al., 2018) . Pharmacological or genetic manipulation of these pathways destabilizes steady-state levels of the protein and this impacts SCA1-like phenotypes in mouse models of the disease (Bondar et al., 2018; Jafar-Nejad et al., 2011; Lai et al., 2011; Park et al., 2013; Pérez Ortiz et al., 2018) . ATXN1 mRNA expression is also tightly regulated post-transcriptionally by the action of RNA binding proteins and microRNAs. Haploinsufficiency at the mouse Pumilio-1 locus (Pum1) or specifically inhibiting microRNAs that bind the ATXN1 3'UTR leads to increased Ataxin-1 expression and this exacerbates phenotypes in disease mouse models (Gennarino et al., 2015; Lee et al., 2008) . Importantly, adeno-associated virus delivery of an artificial anti-ATXN1 microRNA can reduce Ataxin-1 levels in the adult brain, partially rescuing motor phenotypes, cerebellar pathology and transcriptional abnormalities in SCA1 mouse models (Keiser et al., 2014; Keiser et al., 2016) . Given the preclinical efficacy of these approaches, further dissecting the cellular mechanisms that regulate Ataxin-1 and
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The 5' untranslated region (5'UTR) of a mature mRNA is often involved in posttranscriptional gene regulation. Regulatory elements such as upstream AUG codons (uAUGs) , upstream open reading frames (uORF's), recognition motifs for RNA binding proteins (RBPs) and secondary structures within the 5'UTR can impact mRNA stability and efficiency of protein translation (Araujo et al., 2012; Meijer and Thomas, 2002; Mignone et al., 2002; Pickering and Willis, 2005) . Further, alternatively spliced 5'UTR variants can have distinct effects on the expression of the downstream protein (Flouriot et al., 2000; Hughes, 2006; Resch et al., 2009) .
Via the concerted action of one or multiple of these mechanisms, 5'UTRs can act as a type of genetic rheostat, controlling protein output by modulating upstream activity of the translational machinery.
The ATXN1 5'UTR is unusually long, spanning across the first seven exons (971 nucleotides) of the transcript. Experimental evidence supports alternative splicing within the ATXN1 5'UTR but the expression pattern of these splice variants in human brain has not been described (RefSeq NM_000332 and RefSeq NM_001128164) . Interestingly, there are 12 uAUGs, a number of predicted uORFs and RBP binding motifs in the ATXN1 5'UTR that could influence Ataxin-1 protein output. In this study, we focused on characterizing the 5'UTR of ATXN1 and defining its role in the regulation of Ataxin-1, in the context of normal and mutant ATXN1 mRNA transcripts.
Materials and Methods

Analysis of ATXN1 5'UTR expression in human brain
Post-mortem brain tissue from neuropathologically normal (n=3) or SCA1-diagnosed individuals (n=2) was procured from brain banks in accordance to procedures approved by the
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Institutional Review Board at the University of Florida. Total RNA was extracted using Trizol reagent (Thermo Fisher Scientific catalog # 15596026) per manufacturer's recommendations and the RNA integrity number (RIN) assessed in an Agilent Bioanalyzer. All samples had a RIN >6. cDNA was generated by the random primer method using the High Capacity Reverse Transcription kit (Thermo Fisher Scientific catalog # 4368814). PCR was performed using the listed primers and 100 ng of cDNA in an Accuprime Pfx DNA Polymerase kit reaction (Thermo Fisher Scientific catalog # 12344024). Amplicons were resolved on a 2.5% agarose gel and the identity of ATXN1 5'UTR splice variants confirmed by purifying DNA bands using the PureLink Quick Gel Extraction Kit (Thermo Fisher Scientific catalog # K210012) followed by direct Sanger sequencing.
RNA levels of each ATXN1 5'UTR splice variants were quantified by real-time PCR (qPCR) using the Taqman Fast Universal PCR master mix (Thermo Fisher Scientific catalog # 4352042). Custom splice variant-specific qPCR probes and/or primers were designed to span across unique exon junctions. Specificity of these probes/primers was confirmed using the cDNA constructs described below. Relative quantification was performed by the Ct method, normalizing levels of each spliced variant to GAPDH mRNA levels (IDT Assay ID Hs.PT.58.40035104).
Characterization of ATXN1 5'UTR activity using EGFP reporter plasmids ATXN1 5'UTR variants and mutant sequences used in this study were ordered as double stranded gene block fragments from Integrated DNA technology (IDT). Gene block fragments were cloned into the pEGFPN-1 expression plasmid at a unique Nhe I site immediately upstream of the eGFP coding sequence.
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Human embryonic kidney immortalized cells (HEK293T) were maintained in DMEM growth medium containing 10% heat inactivated fetal bovine serum (FBS) and 1% Penicillin/streptomycin in a 37C incubator with 5% CO2. HEK293T cells were plated (1.70 x 10 5 ) in a 12-well vessel and transfected 24-hrs later with 1ug total plasmid DNA using Lipofectamine 3000 (Thermo Fisher Scientific # L3000001). Cells were incubated for an additional 36-hrs prior to total RNA or protein extractions as described below.
Cells were rinsed in 1xPBS and total RNA prepared using Trizol followed by a 30-min treatment with DNAse I (Turbo DNA free kit, Thermo Fisher Scientific #AM1907). cDNA was prepared as described above using 1ug of total RNA. qPCR was performed using 50ng of cDNA. Relative GFP RNA levels were quantified by (Taqman Assay ID Mr04097229_mr) using the delta-delta Ct method and normalizing to GAPDH mRNA levels. Total protein lysates were obtained using 1X RIPA buffer supplemented with a protease inhibitor cocktail (Sigma-Aldrich catalog # 11873580001). After brief sonication, the homogenate was clarified at 14000 rpm for 10 min at 4C and protein concentration calculated (Pierce BCA protein assay kit, Thermo Fisher Scientific catalog # 23225). Total protein samples (10 ug) were prepared in 1x NuPage LDS sample buffer (Thermo Fisher Scientific catalog # NP0007) containing 1x NuPage Reducing agent (Thermo Fisher Scientific catalog # NP0004) and electrophoresed on a NuPAGE 4-12% Bis Tris gel (Thermo Fisher Scientific catalog #NPO321BOX). Samples were transferred onto a PVDF membrane, blocked in 5% milk in TBS-T for 1 hour and immunoblotted using anti-GFP (Thermo Fisher Scientific catalog # A-11122, dilution 1:5000) and anti-beta-Actin antibodies (Sigma-Aldrich catalog # A2228, dilution 1:10000). The PVDF membrane was then incubated with species specific anti-HRP secondary antibodies for 1 hour and detection was performed using West Pico ECL (Thermo Fisher Scientific # PI34080). Protein levels were quantified using ImageJ software. For each sample, GFP levels were first normalized to beta-actin and fold expression next calculated relative to the 5'UTR-EGFP samples.
Allele specific circular PCR ATXN1 gene specific primers were used to perform an ATXN1-specific reverse transcription on human brain-derived RNA (Superscript II Reverse transcriptase, Thermo Fisher Scientific catalog # 18064014). PCR primers containing Xho I restriction sites were designed to amplify the resulting cDNA from exon-1 to exon-8 of the ATXN1 transcript using Phusion High fidelity DNA polymerase (NEB catalog # M0530S). This includes the 5'UTR and the coding region from the start codon to just downstream of the CAG repeats. PCR product was resolved on a 1.2% agarose gel, purified and digested with Xho I to facilitate circularization in a selfligation reaction containing 50ng of DNA and T4 DNA ligase (50 ul ligation reaction overnight at 16C, NEB catalog # M0202) (Liu et al., 2008) . The circular ATXN1 amplicon was used as a template (0.125 ul per 20ul reaction volume) to perform a PCR reaction using a forward primer on exon-8 and a reverse primer on exon-4. This yields a small PCR product that contains both the CAG region and the 5'UTR sequence as shown in (supplementary figure 3).
PacBio Sequencing
PCR amplicons beginning at exon-1 and extending past the CAG repeats in exon-8 were generated from control (n=3) and SCA1 (n=2) human cerebellum-derived ATXN1 cDNA (Phusion High fidelity DNA polymerase, NEB). For each sample, 4 different PCR reactions were pooled prior to purification (Mag-Bind RXN Pure Plus, Omega-Biotek catalog # M1386-00) and resolved on a 6% TBE gel (Thermo Fisher Scientific catalog # EC62652). DNA bands of ~1.7 Kb in size were excised from the gel and extracted using the crush and soak method (Sambrook and Russell, 2006) . Amplicon size was confirmed in the Agilent TapeStation using a DNA5000 screen tape. SMRT bell libraries were constructed using barcoded adaptors for multiplex sequencing following manufacturer's recommendations (PacBio protocol number 100-538-700-03). Briefly, 100 ng of each sample was used in the end-repair/ligation reaction using barcoded
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adaptors from the SMRTbell barcoded adapter complete prep kit -96 (PacBio # 100-514-900).
This was followed by a clean-up step with AMPure magnetic beads at a 1:1 sample to beads ratio (Beckman Coulter # A63881). Barcoded samples were pooled for the DNA damage repair step prior to being exonuclease digested (Exonuclease III and VII) and purified twice with magnetic beads as before. Approximately 100 ng of library was obtained (25% yield) as quantitated by the QUBIT method (ThermoFisher). Final library was sequenced on the RSII machine.
PacBio data analysis
The barcoded library was run through Iso-Seq 3 analysis pipeline. The Iso-Seq 3 workflow is as follow. For each sequence, a circular consensus sequence (CCS) read was generated (min pass=1 and min accuracy=0.8). CCS reads were classified using the LIMA algorithm as full-length (FL) only if PCR primers and barcodes were detected at both the 5' and 3' end. CCS reads with mismatched barcodes or non-FL reads were not used for further analysis. The FL reads were then clustered at the isoform level and polished into high-quality consensus sequences, then mapped to human genome (hg38) using minimap2. Detailed description of the Iso-Seq 3 analysis can be found at https://github.com/PacificBiosciences/IsoSeq_SA3nUP/wiki.
Statistics
Statistical analyses are described within the results section. A total of four biological replicates (n=4) were included in all of the analyses. Briefly, either one-way ANOVA with multiple comparisons analysis (Tukey's test) or repeated-measures ANOVA with multiple comparisons analysis (Sidak's test) were performed depending on the experimental design. In all cases, p<0.05 was considered significant.
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Results
The ATXN1 5'UTR is alternatively spliced and differentially expressed in human brain
To determine if the ATXN1 5'UTR plays a role in regulating Ataxin-1 levels we first characterized its expression pattern in human brain. cDNA was prepared from non-pathological human cerebellar and cortical tissues and amplified using primer pairs anchored in exons 1 and 4 or exons 5 and 8 of the transcript (Figure 1A) . Multiple amplicons were observed when using the exon 1-4 primer pair, indicative of alternative splicing activity (Figure 1B) . Sanger sequencing confirmed the presence of three different ATXN1 5'UTR splice variants: one containing all four exons (Figure 1B, top band) , a second lacking exon-2 ( Figure 1B, middle bands) and a third lacking exons 2 and 3 ( Figure 1B, bottom band) . From hereon we refer to these variants as 5'UTR, 5'UTRd2 and 5'UTRd2,3 respectively. Performing the PCR reaction in the presence of increasing concentrations of betaine yielded a more defined 5'UTRd2 amplicon as confirmed by Sanger sequencing (supplementary figure S1). A similar ATXN1 5'UTR splicing pattern was detected in human fetal brain-derived cDNA (supplementary figure S2).
No alternative splice isoforms were detected between exons 5 and 8 under these conditions ( Figure 1C) . We quantified the ratio between the three main ATXN1 5'UTR variants using custom made, splice isoform-specific quantitative PCR probes (supplementary table 1) with similar amplification efficiencies. Comparing the level of each isoform to that of internal control (dCt) confirmed that the previously undescribed 5'UTRd2,3 splice isoform is the most abundant variant in cerebellar and cortical human brain tissue. We observed a significant increase in cerebellar expression of 5'UTRd2,3 splice isoform as compared to 5'UTR (5'UTRd2,3 vs 5'UTR Tukey's multiple comparison test mean diff= -0.04878, 95%CI= -0.06493 to -0.03266, p<0.001) or 5'UTRd2 (5'UTRd2,3 vs 5'UTRd2 Tukey's multiple comparison test mean diff= -0.04729, 95%CI= -0.06342 to -0.03115, p<0.001). Similar increase in 5'UTRd2,3 was observed in the cortex when compared to 5'UTR (5'UTRd2,3 vs 5'UTR Tukey's multiple comparison test mean
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Tukey's multiple comparison test mean diff= -0.04854, 95%CI= -0.07003 to -0.02705, p<0.01).
( Figure 1D) .
The ATXN1 5'UTR participates in the post-transcriptional regulation of Ataxin-1
The ability of the 5'UTR, 5'UTRd2 and 5'UTRd2,3 sequences to regulate gene expression was evaluated using a cell-based EGFP reporter assay. The cDNA sequence of each isoform was placed between the CMV promoter and the EGFP coding sequence of an pEGFP-N1 reporter plasmid to generate three different ATXN1 5'UTR EGFP expression constructs (Figure 2A) . Transient expression of these constructs in HEK293T cells revealed differences in EGFP protein output between the three variants. As shown in figure 2B , the 5'UTRd2,3-EGFP variant showed on average 2.5-fold higher levels of EGFP compared to the 5'UTR-EGFP variant. We consistently observed a gradual increase in EGFP output when comparing the 5'UTR to the 5'UTRd2 (Tukey's multiple comparisons test, mean diff= -0.807, 95%CI= -1.256 to -0.3570, p<0.01) and 5'UTRd2,3 variants (Tukey's multiple comparisons test, mean diff= -1.516, 95%CI= -1.966 to -1.066, p<0.0001). Given that steady-state mRNA levels were unchanged (Figure 2B, rightmost panel) , differences in EGFP protein output could not be attributed to changes in transcriptional activity or mRNA stability between the variants.
Similar results were observed using a Luciferase-based reporter assay under the control of an SV40 promoter (not shown). These results provide the first experimental evidence linking the ATXN1 5'UTR to post-transcriptional gene regulation.
ATXN1 5'UTR regulates gene expression in part via upstream AUG scanning
The ATXN1 5'UTR variant contains 12 upstream, out-of-frame AUGs (uAUGs) and at least 4 predicted upstream opened-reading-frames (uORFs) (Figure 3A) . To understand the
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role of these upstream elements in regulating Ataxin-1 levels, we generated new 5'UTRand 5'UTRd2,3-EGFP expression constructs in which all uAUG codons were deleted. These new vectors were termed 5'UTR(-ATG)-EGFP and 5'UTRd2,3(-ATG)-EGFP respectively ( Figure   3B ). We focused on these two variants because they displayed the lowest (5'UTR) and highest (5'UTRd2,3) level of EGFP protein output.
Deleting all 12 uAUGs in the 5'UTR sequence (5'UTR(-ATG)-EGFP) led to a >3-fold increase in EGFP protein output when compared to the parental 5'UTR-EGFP construct (Tukey's multiple comparisons test, mean diff= -2.296, 95%CI= -3.546 to -1.045, p<0.001).
Similarly, deleting uAUGs in the 5'UTRd2,3 variant (5'UTRd2,3(-ATG)-EGFP) led to a >2-fold increase in EGFP when compared to the wild-type 5'UTRd2,3 variant ( Figure 3C ) (Tukey's multiple comparisons test, mean diff= -2.007, 95%CI= -3.257 to -0.7561, p<0.01). Intriguingly, deletion of uAUGs abolished the previously observed difference in EGFP protein output between the 5'UTR and 5'UTRd2,3 variants (Figures 2B and 3B) suggesting a role for uAUGs in the gradient-like differences in expression between the variants. To further confirm the impact of uAUGs, all 12 uAUGs in the ATXN1 5'UTR were mutated to non-conforming AAG codons ( Figure 3C) . Again, we observed a marked increase in EGFP output when comparing the 5'UTR carrying uAUG-to-AAG mutations to the wild-type 5'UTR variant (Figure 3C) . Thus, either deleting or mutating uAUGs led to similar increases in EGFP output, confirming a role for uAUGs in the ATXN1-5'UTR-mediated regulation of protein output.
As noted before, qPCR analysis showed no significant differences in the steady-state mRNA levels of the 5'UTR, 5'UTRd2 or 5'UTRd2,3-EGFP variants (Figure 2B ) suggesting that differences in translational efficiencies likely underlie differences in protein output. To further explore this observation, we asked if differences in mRNA stability could explain the observed differences in protein output between the uAUG-containing and uAUG-deleted ATXN1-5'UTR constructs. We used actinomycin-D, a transcriptional inhibitor, to analyze the mRNA Altered ATXN1 5'UTR splicing activity in the SCA1 brain Based on our findings, one could hypothesize that SCA1-associated changes in ATXN1-5'UTR alternative splicing could lead to altered Ataxin-1 levels, impacting disease onset and/or progression. With this in mind, we sought to characterize the expression of ATXN1-5'UTR splice isoforms in the context of SCA1. As before, cDNA generated from human postmortem SCA1 cerebellar and motor cortex tissue was subjected to PCR using primers depicted in figure 1A .
The three major ATXN1-5'UTR variants were once again detected (Figure 4A) . However, qPCR analysis revealed a SCA1-associated increase in the levels of the 5'UTRd2 variant when compared to controls (Figure 4B) . Intriguingly, the abnormal increase in 5'UTRd2 expression
was most pronounced in SCA1 cerebellar tissue and not observe in the motor cortex of SCA1 patients.
Given that the only difference between normal and SCA1 brains is the expression of a mutant ATXN1 allele, we asked whether the increase in 5'UTRd2 levels in SCA1 cerebellum was due to allele-specific alterations in ATXN1 5'UTR splicing. We used cDNA from control and SCA1 brains to generate a ~1.7kb ATXN1 PCR amplicon spanning the 5'UTR region to just downstream of the CAG repeats (Figure 4C) . This amplicon was circularized (see methods) and used in a second PCR step to generate smaller size products containing both the CAG repeat region and the first four exons of the 5'UTR ( Figure 1A) (supplementary figure S4) .
Although this approach allowed us to detect expression of wild-type and mutant ATXN1 5'UTRd2 splice variants (Figure 4C, right panel) , it was unable to facilitate reliable quantification of wild-type and mutant ATXN1 5'UTRd2 levels.
As an alternative approach, we generated PacBio SMRT bell libraries using the same control (n=3) and SCA1 (n=2) cerebellum-derived ~1.7kb ATXN1 amplicon. Analysis of the PacBio sequencing results confirmed the SCA1-associated increase in 5'UTRd2 levels. As shown in figure 5A, we found that 5'UTRd2 reads constituted on average ~12% of the total reads in control cerebella, that percentage shifted to 28.5% and 29.9% in the SCA1 cerebellar tissue we analyzed. Intriguingly, the percentage of 5'UTRd2,3 reads between control and SCA1 tissue was remarkably similar. Since the amplicon used for PacBio sequencing spanned across the CAG repeats, we designed a bioinformatics approach to quantify the levels of 5'UTRd2 variants arising from either wild-type or mutant (CAG expanded) ATXN1 alleles in SCA1 cerebellum. We failed to detect differences in the percentage of 5'UTRd2 splice variants arising from wild-type or CAG expanded ATXN1 transcripts ( Figure 5B) . Together, these experiments show alterations in ATXN1 5'UTR splicing of wild-type and mutant ATXN1 transcripts in SCA1 cerebellum.
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Discussion
Previous studies have shown that Ataxin-1 levels are tightly regulated by posttranslational and post-transcriptional cellular mechanisms. For example, phosphorylation by MSK1 and PAK1 modulate Ataxin-1 by impacting the stability of the protein (Bondar et al., 2018; Park et al., 2013) while a number of microRNAs including miR-19, -101 and -130 as well as the RNA binding protein Pumilio-1 regulate expression by binding the ATXN1 3'UTR, (Gennarino et al., 2015; Lee et al., 2008) . Precise regulation of Ataxin-1 expression by multiple mechanisms underscores its biological significance. Here we show that the unusually long ATXN1 5'UTR, which undergoes alternative splicing, also participates in the regulation of Ataxin-1 by acting as a type of genetic rheostat to modulate Ataxin-1 expression. We find that the presence of up to twelve, out-of-frame upstream AUGs (uAUGs) in the ATXN1 5'UTR impairs translational efficiency of the transcript. Furthermore, we provide evidence of alterations in 5'UTR splicing in human SCA1 cerebellar tissue. Together, these data uncover yet another layer of Ataxin-1 regulation, inform on a previously unappreciated function of the ATXN1 5'UTR and provide evidence for its potential involvement in SCA1 pathogenesis. 5'UTR elements are known to play a role in the control of translational initiation (Calvo et al., 2009; Capell et al., 2014; Meijer and Thomas, 2002; Pichon et al., 2012; Sobczak and Krzyzosiak, 2002) . Within a given transcriptional unit, changes to the 5'UTR sequence can be achieved by varying promoter usage or via alternative splicing (Barrett et al., 2012; Flouriot et al., 2000; Sobczak and Krzyzosiak, 2002) . Programing 5'UTR sequence diversity can result in protein output differences between variants, for example on a cell type basis or in response to environmental stimuli (Vattem and Wek, 2004) . As we showed, the ATXN1 5'UTR undergoes alternative splicing. To our surprise, we find that a previously unreported ATXN1 5'UTR variant, which lacks exons 2 and 3 (5'UTRd2,3), is the most abundant transcript in human brain. In cellbased assays, the 5'UTRd2,3 sequence mediated the highest level of protein output when A C C E P T E D M A N U S C R I P T compared to the 5'UTRd2 and 5'UTR variants. Analysis of these two exons revealed the presence of two out-of-frame uAUGs and a predicted short uORF. Structurally, RNA folding software predicts the presence of a small hairpin-like structure within this region (supplementary figure S6) (Zuker, 2003) . Thus, a number of possible mechanisms may contribute to the observed, gradient-like differences in protein output between these three 5'UTR isoforms. Finally, PacBio sequencing confirmed the presence of these and other, less abundant, 5'UTR variants (supplementary figure S5) . Importantly it uncovered an abnormal, SCA1 cerebellar-specific increase in the levels of 5'UTRd2. The impact that this shift in 5'UTR splicing has on the levels of Ataxin-1 and the progression of SCA1 pathology are now the focus of ongoing studies.
Effectively translated transcripts are characterized by short, relatively unstructured 5'UTRs, while long 5'UTRs are typically present in transcripts associated with low protein output (Kochetov et al., 1998; Pickering and Willis, 2005) . We find that, in contrast to the average length of a human 5'UTR (~200 nucleotides), the three major ATXN1 5'UTR splice variants range from 807 to 971 nucleotides in length. Not surprisingly, the shortest of the three variants, 5'UTRd2,3, displayed the highest level of protein output in our cell-based assay. Phylogenetic analysis of the ATXN1 5'UTR sequence shows that, although the sequence varies between species its length appears to be conserved, suggesting evolutionary pressure to produce a transcript that mediates low protein output.
Out-of-frame uAUGs also play a key regulatory role within 5'UTRs, impacting translational efficiency of the downstream primary open reading frame (Kochetov, 2008; Meijer and Thomas, 2002; Yun et al., 2012) . The ATXN1 5'UTR contains a cluster of five, out-of-frame uAUGs immediately upstream of the main ORF, a second cluster of five uAUGs near the middle of the 5'UTR and two additional uAUGs within exons 2 and 3. We find that deleting or mutating the 5'UTR uAUGs leads to between 2and 3-fold increases in protein output. This finding is in
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agreement with the observation made by Dvir et al regarding the ~2.4 fold suppression in protein output associated with the presence of uAUGs in yeast transcripts (Dvir et al., 2013) .
The fact that only two of twelve uAUGs in the ATXN1 5'UTR are impacted by alternative splicing suggests a cellular need to maintain strong uAUG-dependent regulation of Ataxin-1 protein output.
Modulating Ataxin-1 expression at the RNA or protein level holds significant therapeutic potential in SCA1. Our finding that the ATXN1 5'UTR is alternatively spliced and that it plays a role in the regulation of Ataxin-1 protein output provides immediate and long-term opportunities in therapeutic development. For example, identification of the 5'UTRd2,3 variant as the major transcript in human brain should now be considered in the design of oligonucleotide-based therapies. Also, strategies that shift ATXN1 5'UTR splicing equilibrium away from 5'UTRd2,3 towards the 5'UTR variant should result in moderate but significant reductions in Ataxin-1 expression. One could speculate that the SCA1-associated increase in 5'UTRd2 levels, a variant that mediates less protein output than the 5'UTRd2,3, may be an attempt by affected cell types to counteract mutant Ataxin-1 gain-of-function toxicities (Rousseaux et al., 2018) In summary, the ATXN1 5'UTR participates in the regulation of Ataxin-1 levels. A number of regulatory elements within the ATXN1 5'UTR including length, structure, alternative splicing, uAUGs and uORFs appear to act in concert to maintain low levels of Ataxin-1 protein output. It is important to further investigate the role that this type of Ataxin-1 regulation plays in cellular homeostasis and to engineer ways in which the 5'UTR-based regulation can be M A N U S C R I P T cDNA sequence of each ATXN1 5'UTR splice isoform was cloned in between the CMV promoter and EGFP coding sequence in the pEGFPN1 reporter plasmid. B) HEK293T cells were transiently transfected with 5'UTR-EGFP, 5'UTRd2-EGFP and 5'UTRd2,3-EGFP constructs. GFP protein was assessed by western blotting and GFP RNA levels were measured by qPCR (ddCt method). Both, GFP protein and RNA were first normalized to housekeeping genes (B-actin and GAPDH respectively) and represented as fold expression change over 5'UTR GFP.
Figure 3 ATXN1 5'UTR regulates gene expression in part via upstream AUG scanning. A)
Schematic of uAUG's (purple arrows) and predicted uORF's (blue line) in the ATXN1 5'UTR. B) uAUGs (purple arrows) in the 5'UTR ATXN1 and 5'UTRd2,3 ATXN1 were deleted to generate new EGFP constructs. Representative western blot of cells expressing 5'UTR GFP, 5'UTR(-ATG) GFP, 5'UTRd2,3 GFP and 5'UTRd2,3(-ATG) GFP expression constructs. C) The uAUGs in the 5'UTR ATXN1 were mutated to AAG codons and cloned upstream of EGFPN1 coding sequence. 5'UTR GFP, 5'UTR(-ATG) GFP and 5'UTR(AAG) GFP were expressed in HEK293T
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A C C E P T E D M A N U S C R I P T cells and immunoblotted for GFP. D) Cells transfected with EGFPN1, 5'UTR GFP and 5'UTR(-ATG) GFP were either treated with actinomycin-D to block transcription or with vehicle DMSO. GFP RNA levels for each sample were assessed 6 hours post treatment by normalizing to its DMSO treated counterpart at that time point. 
